Fair call on managment performance over the past 12 months, but I don't think you can dump Bret Mattes into that pot.
Unlike what might have happened (and I think we were all prepared for the usual vacuous but satisfying pump), whatever he brings to the table should at least be economically sound under scrutiny. If that is accompanied by the long awaited pump with minimal dilution via an expected and univited placement, (both Kyle's job) all the better.
I am dreaming of a full corporatisation for ChemLab and I think they are heading that way due to recent hirings and documented business expansion plans, but given it is public service maybe this is a bridge too far for this FY.
But with fingers on the pulse of both the cutting edge of biotech and O&G sectors I doubt this will remain quiet for ever; as Gizzard said, a further pause whilst the dead options fade from immediate memory.
And as you say currently at cash backing.
NDL Price at posting:
3.0¢ Sentiment: Hold Disclosure: Held
